Ammonia‐lowering strategies for the treatment of hepatic encephalopathy
dc.contributor.author | Rose, Christopher | |
dc.date.accessioned | 2020-11-12T13:04:38Z | |
dc.date.available | NO_RESTRICTION | fr |
dc.date.available | 2020-11-12T13:04:38Z | |
dc.date.issued | 2012-08-08 | |
dc.identifier.uri | http://hdl.handle.net/1866/24043 | |
dc.publisher | Wiley | fr |
dc.subject | Brain | fr |
dc.subject | Hepatic | fr |
dc.subject | Metabolism | fr |
dc.subject | Neurological | fr |
dc.subject | Therapeutics | fr |
dc.title | Ammonia‐lowering strategies for the treatment of hepatic encephalopathy | fr |
dc.type | Article | fr |
dc.contributor.affiliation | Université de Montréal. Faculté de médecine. Département de médecine | fr |
dc.identifier.doi | 10.1038/clpt.2012.112 | |
dcterms.abstract | Hyperammonemia leads to neurotoxic levels of brain ammonia and is a major factor involved in the pathogenesis of hepatic encephalopathy (HE). Ammonia‐lowering treatments primarily involve two strategies: inhibiting ammonia production and/or increasing ammonia removal. Targeting the gut has been the primary focus for many years, with the goal of inhibiting the generation of ammonia. However, in the context of liver failure, extrahepatic organs containing ammonia metabolic pathways have become new potential ammonia‐lowering targets. Skeletal muscle has the capacity to remove ammonia by producing glutamine through the enzyme glutamine synthetase (amidation of glutamate) and, given its large mass, has the potential to be an important ammonia‐removing organ. On the other hand, glutamine can be deaminated to glutamate by phosphate‐activated glutaminase, thus releasing ammonia (ammonia rebound). Therefore, new treatment strategies are being focused on stimulating the removal of both ammonia and glutamine. | fr |
dcterms.isPartOf | urn:ISSN:0009-9236 | fr |
dcterms.isPartOf | urn:ISSN:1532-6535 | fr |
dcterms.language | eng | fr |
UdeM.ReferenceFournieParDeposant | 10.1038/clpt.2012.112 | fr |
UdeM.VersionRioxx | Version acceptée / Accepted Manuscript | fr |
oaire.citationTitle | Clinical pharmacology and therapeutics | fr |
oaire.citationVolume | 92 | fr |
oaire.citationIssue | 3 | fr |
oaire.citationStartPage | 321 | fr |
oaire.citationEndPage | 331 | fr |
Fichier·s constituant ce document
Ce document figure dans la ou les collections suivantes
Ce document diffusé sur Papyrus est la propriété exclusive des titulaires des droits d'auteur et est protégé par la Loi sur le droit d'auteur (L.R.C. (1985), ch. C-42). Il peut être utilisé dans le cadre d'une utilisation équitable et non commerciale, à des fins d'étude privée ou de recherche, de critique ou de compte-rendu comme le prévoit la Loi. Pour toute autre utilisation, une autorisation écrite des titulaires des droits d'auteur sera nécessaire.